Category - Developments

Titan Pharmaceuticals (NASDAQ:TTNP) and its marketing partner, closely-held Braeburn Pharmaceuticals, received a potential shot in the arm as the White House called for expanded access to treatment in the war on opioid...

Closely-held ZappRx closed a $25-million Series B funding led by Qiming US Healthcare Fund, with participation from SR One, which led ZappRx’s Series A round in 2014, and GV, formerly Google Ventures. ZappRx is a...

IntelGenx (OTCQX:IGXT; TSX-V:IGX) and RedHill Biopharma (NASDAQ, TASE:RDHL) announced that the Ministry of Health of Luxembourg has granted national marketing authorization for RIZAPORT (5 mg and 10 mg), an oral thin...

Closely-held CSA Medical announced publication of a research letter in the American Journal of Respiratory and Critical Care Medicine (AJRCCM), which highlights the initial safety data of the company’s RejuvenAir System...

A patient using Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine six-month implant containing buprenorphine as a new treatment in the battle against heroin and prescription painkiller addiction has documented his...

BioTime (NYSE MKT:BTX) has created AgeX Therapeutics, which will consolidate certain BioTime subsidiaries and programs in the field of interventional gerontology. The formation of AgeX continues the implementation of...

Jaguar Animal Health (NASDAQ:JAGX) and closely-held Napo Pharmaceuticals, which are in the process of merging, updated their commercial activities. Jaguar is launching a national TV advertising campaign this month for...

IntelGenx (OTCQX:IGXT; TSXV:IGX) and Tetra Bio-Pharma (CSE:TBP; OTC:GRPOF) signed a definitive agreement to develop and commercialize a drug product containing the cannabinoid, Dronabinol, for the management of anorexia...

Jaguar Animal Health (NASDAQ:JAGX) and closely-held Napo Pharmaceuticals have entered into a definitive merger agreement by unanimous approval by the boards of both companies. Under the accord, Jaguar’s stockholders and...

3D Signatures (TSX-V:DXD; OTCQB:TDSGF; FSE:3D0) has successfully completed internal analytical assay validation for its Hodgkin’s lymphoma (HL) test (Telo-HL) according to FDA guidelines. Assay validation of Telo...